To further evaluate the efficiency of FcRH5 CAR-T cells in the more clinically relevant context, we sought to explore whether patient-derived T cells engineered to express FcRH5-specific CAR could efficiently recognize and eradicate autologous MM cells. This evidence concerns the gene FCRL5 and Miyoshi myopathy.